ME vs. FHTX, VERU, CDT, ACIU, ALDX, HOWL, EBS, QURE, PBYI, and TSVT
Should you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Foghorn Therapeutics (FHTX), Veru (VERU), Conduit Pharmaceuticals (CDT), AC Immune (ACIU), Aldeyra Therapeutics (ALDX), Werewolf Therapeutics (HOWL), Emergent BioSolutions (EBS), uniQure (QURE), Puma Biotechnology (PBYI), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical preparations" industry.
Foghorn Therapeutics (NASDAQ:FHTX) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 36.1% of 23andMe shares are held by institutional investors. 9.1% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 27.6% of 23andMe shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Foghorn Therapeutics had 2 more articles in the media than 23andMe. MarketBeat recorded 9 mentions for Foghorn Therapeutics and 7 mentions for 23andMe. 23andMe's average media sentiment score of 0.38 beat Foghorn Therapeutics' score of 0.29 indicating that Foghorn Therapeutics is being referred to more favorably in the media.
23andMe has a net margin of -210.48% compared to 23andMe's net margin of -274.23%. 23andMe's return on equity of 0.00% beat Foghorn Therapeutics' return on equity.
Foghorn Therapeutics has higher earnings, but lower revenue than 23andMe. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
Foghorn Therapeutics has a beta of 3.15, meaning that its stock price is 215% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Foghorn Therapeutics received 20 more outperform votes than 23andMe when rated by MarketBeat users. However, 63.16% of users gave 23andMe an outperform vote while only 59.26% of users gave Foghorn Therapeutics an outperform vote.
Foghorn Therapeutics presently has a consensus target price of $14.50, suggesting a potential upside of 149.57%. 23andMe has a consensus target price of $0.47, suggesting a potential downside of 21.29%. Given 23andMe's stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than 23andMe.
Summary
Foghorn Therapeutics beats 23andMe on 12 of the 18 factors compared between the two stocks.
Get 23andMe News Delivered to You Automatically
Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
